LASERS & VASCULAR ROSACEA: FROM PHYSICAL PRINCIPLES TO CLINICAL ENDPOINTS

Therapeutic rationale and targets

Vascular rosacea encompasses a range of clinical manifestations associated with involvement of the facial blood vessels.

It may present as diffuse redness without individually discernible vessels, termed erythrosis, or as visible telangiectasias of varying caliber, corresponding to couperose. These presentations may be accompanied by transient vasomotor episodes, described by patients as flushing, that occur independently of the persistent clinical appearance.

The clinical treatment target is the blood vessel, while the optical target is the oxyhemoglobin it contains. Light energy absorbed by oxyhemoglobin is converted into heat, which subsequently spreads by conduction to the vessel wall. The objective is to achieve controlled, sufficiently targeted heating to reach and damage the vessel wall while avoiding thermal diffusion into surrounding tissues.

Pulse duration and endpoints

Within this framework, pulse duration is the central parameter, as it determines the balance between efficacy and tolerability according to vessel caliber.

For fine vessels, short pulses, generally ranging from 0.45 to 3 ms, achieve selective photothermolysis. The rapid rise in intraluminal temperature causes blood coagulation, followed by vessel wall damage and rupture. The expected endpoint is distinct, well-demarcated purpura, appearing as a bruise, without opalescence. This clinical response makes it the reference approach for treating erythrosis.

Conversely, for larger-caliber vessels, longer pulses, approximately 10 to 30 ms, produce more gradual heating and slower thermal transfer to the vessel wall, favoring selective photocoagulation. The desired endpoint is vasospasm, manifested by vessel contraction or reduced visibility, without purpura. This clinical response corresponds to the preferred approach for treating couperose.

An inappropriate pulse duration may result in incomplete occlusion, rendering treatment ineffective, or increase the risk of adverse effects such as burns, edema, or postinflammatory hyperpigmentation.

Intermediate pulse durations, around 6 ms, represent a transition zone in which treatment may favor either photothermolysis or photocoagulation, depending on the fluence and clinical context. They are frequently used to treat fine telangiectasias.

Wavelength, penetration depth, and safety across skin phototypes

The principal wavelengths commonly used in vascular laser treatment are 532 nm, 577 nm, 585–595 nm, and 1,064 nm.

Wavelength primarily determines beam penetration depth, laser selectivity for oxyhemoglobin, and the safety margin with respect to melanin. In practice, longer wavelengths penetrate more deeply into tissue and are less strongly absorbed by melanin, improving safety in darker skin phototypes.

The 532-nm potassium titanyl phosphate (KTP) laser is highly effective for fine, superficial vessels. However, its substantial absorption by melanin increases the risk of adverse effects in higher skin phototypes.

Yellow wavelengths, 577 nm or 585–595 nm with the pulsed dye laser (PDL), provide a frequently used compromise for treating erythema and superficial telangiectasias.

The 1,064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser penetrates more deeply and is only weakly absorbed by melanin, allowing treatment of larger, deeper vessels. However, its efficacy and tolerability depend heavily on precise settings and pulse delivery technique.

Spot size, fluence, and coordinated parameter selection

Spot diameter influences beam penetration depth. In practice, with other parameters held constant, a larger spot allows deeper penetration, up to a threshold beyond which the additional benefit becomes marginal.

Fluence, expressed in J/cm², describes the energy delivered per unit area, but it must never be interpreted in isolation.

Clinical outcomes depend primarily on the appropriate combination of wavelength, pulse duration, and spot diameter. Fluence must therefore be adjusted to achieve the desired endpoint without inducing nonspecific thermal diffusion into surrounding tissues.

Cooling as a safety parameter

Cooling should be considered a safety parameter in its own right. It protects the epidermis, improves treatment tolerability, and reduces patient discomfort.

Whether delivered through contact cooling, cryogen spray, or cold air, the decisive factors are synchronization with laser pulse delivery and consistent cooling throughout the session.

Pulse delivery technique and treatment scheduling

Excessive pulse overlap, or stacking, should be avoided, as it is frequently poorly tolerated. Multiple passes may nevertheless be considered, provided sufficient time is allowed between passes, since some endpoints may appear after a delay.

Treatment of vascular rosacea requires an average of three sessions, spaced six to twelve weeks apart. Strict photoprotection before and after treatment is essential to minimize the risk of pigmentary adverse effects.

Conclusion

Precise identification of the target, in terms of vessel caliber and depth, is an essential prerequisite for treatment.

It determines laser selection by wavelength, the intended mechanism, selective photothermolysis or photocoagulation, and consequently the appropriate pulse duration and associated parameters, particularly fluence, spot size, and cooling modality.

Within this systematic approach, the clinical endpoint is the key tool for guiding treatment.

Have a successful treatment session!